fda bpc-157 category 2 bulk drug substance list Legal Status: Regulations and Compounding BPC-157 FDA Approval Status 2026:

The decision to pursue compounded access depends on cost tolerance, denial reason, and timeline

Storage: 28C (refrigerated after reconstitution)

This unique mechanism enables BPC-157 to promote healing throughout the entire wound repair process from initial inflammation through final tissue remodeling phases

One day after the addition of growth hormone to the BPC 157-treated tendon fibroblasts, cells were washed once with 1xPBS, followed by adding 1 mL DMEM containing 0.05 mg/mL 3-[4,5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT)

The American Academy of Family Physicians and NIH identify the following clinical manifestations: Fatigue and generalized weakness Megaloblastic anemia (abnormally large, immature red blood cells) Tingling or numbness in the hands and feet (peripheral neuropathy) Difficulty walking and balance problems Cognitive disturbances including memory difficulty and confusion Mood changes, including depression and irritability Glossitis (swollen, inflamed tongue) Early symptoms such as fatigue and mild tingling are often attributed to stress, aging, or other conditions